1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Indian Acne Market Report for 2016-2025

Indian Acne Market Report for 2016-2025

  • December 2017
  • 108 pages
  • ID: 5251484
  • Format: PDF
  • EffeMarket

Summary

Table of Contents

Search Inside

Acne vulgaris, also known as acne, is a common, chronic, inflammatory disease of the glands that produce sebum (sebaceous follicles). This disease results in the formation of inflamed elevations (papules, pustules, nodules, and cysts), comedones (blackheads and whiteheads), and scars on the skin.

Acne is one of the most common disorders treated by dermatologists and other healthcare providers. More than 90 percent of world population is affected by acne at some point in their life. Although acne is a skin disease, it can lead to prominent emotional and psychological issues.

Several studies have confirmed that acne can affect a person’s quality of life, self-esteem, and mood adversely. Acne is a chronic, inflammatory skin condition with a multi-factorial pathogenesis. The source is hormonal changes during puberty and it is then further exacerbated by genetic and other factors.

Apart from the belief that acne results from sebaceous gland hyperplasia, abnormal follicular differentiation with increased keratinization, microbial hyper-colonization of the follicular canal, and increased inflammation primarily through activation of the adaptive immune system may also be contributors. There are various types of acne, such as acne vulgaris, acne rosacea, acne cosmetica, acne fulminans, and acne mechanica.

Among them all, acne vulgaris is the most common, with prevalence in 99 percent of the acne cases. Acne vulgaris is a common inflammatory skin disease characterized by inflammatory or non-inflammatory lesions.
The prevalence of acne vulgaris globally was 681.2 million in 2016. This was an increase of 10 percent from 612 million in 2006.

In 2010, acne ranked 8thin the list of most prevalent diseases in the world, with a global prevalence of 645 million. Approximately 80 percent of people are affected by acne between the onset of puberty and 30 years of age.

By the end of 2026, the number of people affected by acne in India is estimated to reach 23 million at a compound annual growth rate (compound average growth rate) of 0.5 percent. Females are more prone to acne as compared to males in India. In India, change in annual years of healthy life lost since 1990 to 2013 due to acne is -0.2 percent.

Dermatologic problems can result in psychosocial effects that drastically affect patient’s lives. More than a cosmetic nuisance, skin disease can produce anxiety, depression, and other psychological problems that affect patient’s lives in ways comparable to arthritis or other disabling illnesses.

Even though antibiotics play a key role in acne management, the increase in acnes resistance is a matter of concern. The issue of antibiotic resistance also impacts the prescribing patterns and treatment algorithms.
The standard of care for the treatment of mild-to-moderate acne is topical therapy.

There are two treatment guidelines for treatment available by the American Academy of Dermatology and European Union Group. The currently available therapeutic options for acne include several treatment approaches such as retinoids, antibacterial washes, antibiotic pills, lasers, pulsed-light therapies, photodynamic therapy, and systemic isotretinoin.

There are multiple new breakthroughs we may see in the near future, which may include molecules with novel mechanisms and more effective dosage forms. The acne vulgaris product pipeline comprises the diverse set of molecules with the majority of products in early-stage development.

The global acne product pipeline comprises a total of 64 programs at various stages of clinical development. 41 percent of products are in the preclinical and discovery stage. There are multiple promising molecules in clinical development that may potentially change the acne treatment approach in future.

Despite the size of the acne patient population, innovation in the acne therapy has remained limited over the past 20 years. Most of the innovation in acne therapy has involved reformulation of drugs with improved vehicles or development of a combination of approved products.

Poor adherence is one of the critical and negatively impacting factors affecting acne treatment outcomes. Moreover, limited patient education and awareness about acne treatment is also a roadblock to successful treatment.

Topical formulations are perhaps among the most challenging products to develop regarding delivery of a drug to a target site. Also, foams, micro lipid carriers (such as liposomes), microsphere, colloidal delivery systems, porous materials, and combination therapy options are also explored by the companies to come up with new drug delivery solutions to enhance the efficacy of the treatment.

The acne therapy market is moving from mono therapy towards combination therapy options. The most likely reason is higher efficacy of combinations that consider the multi-factorial pathogenesis of acne, reduced resistance levels, and the ease of single product use versus two separate mono therapies.

This report provides in-depth market analysis of the global dermatology market, OTC dermatology product market and acne market. The market size for dermatology therapeutics is expected to grow considerably, from USD19.8 billion in 2016 to USD41.2 billion in 2026, at a compound average growth rate of 8 percent. The global OTC dermatology products market was worth USD114 billion in 2016.

Acne treatments take a considerable share of dermatology OTC product market. Also, increasingly various prescription acne treatments are becoming qualified as OTC products due to their history of long-term safety and efficacy. Products such as Benzoyl peroxide, Salicylic acid, and their combinations are largely moving into the OTC space. Accutane has been top-selling product in the acne prescription market with sales of USD 1.2 billion in 2016.

The Indian dermatology market grew from USD608 million in 2012 to USD1100 million in 2016, with five years compound average growth rate of 12.59 percent. The acne market has grown from USD48 million in 2012 to USD78.5 million in 2016. Over the course of 5 years, the acne prescription market grew at compound average growth rate of 10.34 percent.

In line with the global market trend, the Indian market is also dominated by topical products for the treatment of acne vulgaris. The Indian acne market is expected to grow from USD78.5 million in 2016 to USD164 million by 2026 with a compound average growth rate of 7.65 percent. In 2016 topical products hold 72 percent (USD57 million) of market share by value vs.

oral products holding 28 percent (USD21 million) market share. Combination products hold more than 35 percent market share by value, and it is expected to grow further reaching to 48 percent by 2026.

In the Indian acne market, the top 10 companies hold more than 55 percent of the market by value. The market is crowded, with more than 50 pharmaceutical companies actively marketing their products in the acne therapy segment. Even though the market is largely dominated by local pharmaceuticals companies, multinational pharmaceuticals companies, such as Galderma, Janssen, Abbott, GSK and, Menarini together hold a considerable market share by value (12 percent) and are among the top 20 companies in acne therapy space.

The top assignee is Nestle, with 133 patents, followed by Allergan with 70 patents. Most of Nestlé’s patents belong to its subsidiary, Galderma, which is a Switzerland-based pharmaceutical subsidiary specializing in research and development (R&D) and marketing of dermatological solutions.

The patent with the maximum impact factor (maximum number of citations) is focused on oleaginous pharmaceutical and cosmetic foam for the treatment of acne this patent was cited by 91 patents. Among the top assignees provided by Market research, Nestle (Galderma), Allergan, Dow Chemical (DowDuPont), GlaxoSmithKline, and Sun Pharma appear as top assignees in the intellectual property (patent) search as well. The inventors with the maximum number of fillings are Donella, John E, and Mallard Claire.

Donella. John E is the most active inventor of Allergan, and Mallard Claire has been the most active inventor for Nestle.

Companies profiled in this report include Vyome Biosciences, Sun Pharma, Hegde and Hegde Pharma, Mankind Pharmaceuticals, Cipla Pharmaceuticals and Glenmark Pharmaceuticals.

Key Questions Answered
1. Detailed disease overview of acne.
2. Global Epidemiology of Acne: Actual & Forecast.
3. India Epidemiology of Acne: Actual and Forecast.
4. India Epidemiology by Severity.
5. India Epidemiology by Gender.
6. Current treatment landscape of acne in Indian market with a list of approved products in each therapy including retinoids, antibiotics, benzoyl peroxide, hormonal therapy, and others.
7. Treatment guidelines by America Academy of Dermatology and European Union Group.
8. Pipeline Analysis of acne by stage of development and molecule type.
9. Detailed analysis of promising drugs in clinical development such as topical Minocycline, Olumacostat Glasaretil, SB2014, Sarecycline HCL, VB1953.
10. Global dermatology market; 2016-2026.
11. Indian dermatology market; 2011-2026.
12. Global dermatology OTC products market; 2016-2026.
13. Indian dermatology OTC product market; 2011-2026.
14. Top selling acne market products; 2016.
15. Indian Acne market; 2011-2026.
16. Overall IP trends in acne market; 2012-2017.
17. Earliest priority country filing trend in acne market; 2012-2017.
18. Acne patent trend by focus area, dosage forms, route of administration and composition; 2012-2017.
19. Acne patent trend by the key patent holder; 2012-2017.
20. Key patent holder in Indian acne market; 2012-2017.
21. Top inventors in acne market; 2012-2017.
22. Company analysis of Vyome Biosciences, Glenmark, Cipla, Mankind Pharma, Sun Pharma and Hegde & Hegde with their pipeline drugs.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Dermatitis Global Market Report 2021: COVID 19 Impact and Recovery to 2030

  • $ 5000
  • April 2021
  • 175 pages

Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc. and Sanofi S.A. The global dermatitis market is expected to grow from $4.82 billion ...

  • World
  • Dermatological Condition
  • Industry analysis
  • Drug Approval

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on